Immunovant receives Investment Bank Analyst Rating Update
Immunovant, Inc. (IMVT) reported Q2 EPS of ($0.41), $0.04 worse than the analyst estimate of ($0.37).
On Wednesday, Immunovant Inc (NASDAQ: NASDAQ:IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd's (NASDAQ: ROIV) Investor Day. IMVT-1402 is a new anti-FcRn...
Last year was a remarkable period for companies to go public via special purpose acquisition companies (SPACs). In 2020, in fact, there were 248 completed deals in the US. In 2019,...
Over the past several quarters, a large number of companies have gone public in the US. Many, such as Airbnb (NASDAQ:ABNB), Asana (NYSE:ASAN), DoorDash (NYSE:DASH), Jfrog...
Special purpose acquisition companies (SPACs), which we recently covered}}, are currently among the hottest ways for company's to go public in equity markets. In a nutshell, a SPAC...
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. The Company's product candidate, batoclimab, is a fully human, monoclonal antibody targeting the neonatal fragment crystallizable receptor. Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for Myasthenia Gravis (MG), Thyroid Eye Disease (TED) and Warm Autoimmune Hemolytic Anemia (WAIHA). The Company is conducting a phase I drug-drug interaction (DDI) study in healthy volunteers to characterize the pharmacokinetic (PK) profile of atorvastatin with and without the coadministration of batoclimab.
|Average||18.25 (+0.27% Upside)|
|No. of Analysts||8|